Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (386)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT04175912 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT04123379 | Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) | active not recruiting | Phase 2 | 48 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2) | active not recruiting | Phase 2 / Phase 3 | 89 | AbbVieINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06040099 | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE(EMERALD-Y90) | active not recruiting | Phase 2 | 58 | AstraZenecaINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04721132 | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | active not recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03937830 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | active not recruiting | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05063565 | TheraSphere With Durvalumab and Tremelimumab for HCC(ROWAN) | active not recruiting | Phase 2 | 100 | Boston Scientific CorporationINDUSTRY | 5 | Aug 26, 2026 | clinicaltrials |
| NCT05775159 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | active not recruiting | Phase 2 | 294 | AstraZenecaINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT04550481 | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | active not recruiting | Phase 2 | 35 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05211323 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection(JUPITER 04) | active not recruiting | Phase 2 / Phase 3 | 427 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT05564403 | Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | active not recruiting | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | active not recruiting | Phase 2 | 4 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | active not recruiting | Phase 2 | 72 | Coherus Oncology, Inc.INDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT06096779 | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis(Kirros) | active not recruiting | Phase 2 | 30 | Genentech, Inc.INDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | active not recruiting | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04727307 | Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial(AB-LATE02) | active not recruiting | Phase 2 | 202 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658105 | Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI(Ad-rHCC) | active not recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07646717 | Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma(LPHAIC for ICC) | active not recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05507632 | Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 48 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07081633 | Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma(TREMENDOUS-2) | active not recruiting | Phase 2 | 114 | AstraZenecaINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03107416 | Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells | active not recruiting | Phase 1 / Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07138885 | A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma(DRIVE-II) | active not recruiting | Phase 2 | 62 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06045975 | Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure(DUMELEP) | active not recruiting | Phase 2 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05622136 | Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma(STRAT-aHCC) | active not recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT04563338 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | active not recruiting | Phase 2 | 36 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06178588 | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | active not recruiting | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07380633 | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial | active not recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05113186 | Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative(LENVABLA) | active not recruiting | Phase 2 | 32 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT04669496 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | active not recruiting | Phase 2 / Phase 3 | 178 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1) | active not recruiting | Phase 2 | 130 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials